Cardinal Health Inc (CAH) stock
CAHNYSEWholesale-Drugs, Proprietaries & Druggists' SundriesFiscal year ends June 30
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Aug 11, 2026Score 16/3027% above fair value
$250.48−0.61 (-0.24%)
Close on Oct 30, 2026Market cap $58.26BP/E 34.6Yield 0.81%
Earnings
Cardinal Health's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Oct 29, 2026
Q1 FY2027 · estimated, before the open
Revenue, Q4 FY2026
$63.70B
+5.8% on a year earlier
Non-GAAP diluted EPS attributable to Cardinal Health, Inc., Q4 FY2026
$2.91
$2.08 a year earlier
Latest guidance
Raised
Aug 11, 2026 · 14 items
Quarterly results
Revenue and earnings per share from each of Cardinal Health's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q1 FY2027ended Sep 30, 2026 | Oct 29, 2026Expected | – | – | – | – | – |
| Q4 FY2026ended Jun 30, 2026 | Aug 11, 2026before the open | $63.70B | +5.8% | $1.70 | $2.91 | Release |
| Q3 FY2026ended Mar 31, 2026 | Apr 30, 2026before the open | $60.90B | +10.9% | $1.69 | $3.17 | Release |
| Q2 FY2026ended Dec 31, 2025 | Feb 5, 2026before the open | $65.60B | +18.6% | $1.97 | $2.63 | Release |
| Q1 FY2026ended Sep 30, 2025 | Oct 30, 2025before the open | $64.00B | +22.4% | $1.88 | $2.55 | Release |
| Q4 FY2025ended Jun 30, 2025 | Aug 12, 2025before the open | $60.20B | +0.5% | $1.00 | $2.08 | Release |
| Q3 FY2025ended Mar 31, 2025 | May 1, 2025before the open | $54.90B | 0.0% | $2.10 | $2.35 | Release |
| Q2 FY2025ended Dec 31, 2024 | Jan 30, 2025before the open | $55.30B | -3.7% | $1.65 | $1.93 | Release |
| Q1 FY2025ended Sep 30, 2024 | Nov 1, 2024before the open | $52.30B | -4.6% | $1.70 | $1.88 | Release |
| Q4 FY2024ended Jun 30, 2024 | Aug 14, 2024before the open | $59.90B | +12.0% | $0.96 | $1.84 | Release |
| Q3 FY2024ended Mar 31, 2024 | May 2, 2024before the open | $54.90B | +8.7% | $1.05 | $2.08 | Release |
| Q2 FY2024ended Dec 31, 2023 | Feb 1, 2024before the open | $57.40B | +11.5% | $1.43 | $1.82 | Release |
| Q1 FY2024ended Sep 30, 2023 | Nov 3, 2023before the open | $54.80B | +10.5% | $0.02 | $1.73 | Release |
| Q4 FY2023ended Jun 30, 2023 | Aug 15, 2023before the open | $53.50B | +13.6% | -$0.25 | $1.55 | Release |
| Q3 FY2023ended Mar 31, 2023 | May 4, 2023before the open | $50.50B | +12.7% | $1.34 | $1.74 | Release |
| Q2 FY2023ended Dec 31, 2022 | Feb 2, 2023before the open | $51.50B | +13.2% | -$0.50 | $1.32 | Release |
| Q1 FY2023ended Sep 30, 2022 | Nov 4, 2022before the open | $49.60B | +12.7% | $0.40 | $1.20 | Release |
| Q4 FY2022ended Jun 30, 2022 | Aug 11, 2022before the open | $47.10B | – | $0.50 | $1.05 | Release |
| Q3 FY2022ended Mar 31, 2022 | May 5, 2022before the open | $44.80B | – | -$5.05 | $1.45 | Release |
| Q2 FY2022ended Dec 31, 2021 | Feb 3, 2022before the open | $45.50B | – | $0.17 | $1.27 | Release |
| Q1 FY2022ended Sep 30, 2021 | Nov 9, 2021before the open | $44.00B | – | $0.94 | $1.29 | Release |
| Q4 FY2021ended Jun 30, 2021 | Aug 5, 2021before the open | – | – | – | – | Release |
| Q3 FY2021ended Mar 31, 2021 | May 6, 2021before the open | – | – | – | – | Release |
| Q2 FY2021ended Dec 31, 2020 | Feb 5, 2021before the open | – | – | – | – | Release |
| Q1 FY2021ended Sep 30, 2020 | Nov 5, 2020before the open | – | – | – | – | Release |
| Q4 FY2020ended Jun 30, 2020 | Aug 6, 2020before the open | – | – | – | – | Release |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Cardinal Health's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| Revenue | FY2027 | +3% – +5% | – | New | Aug 11, 2026 |
| Segment profit | FY2027 | +8% – +11% | – | New | Aug 11, 2026 |
| Segment profit | FY2027 | $200.00M – $220.00M | – | New | Aug 11, 2026 |
| Non-GAAP earnings per sharenon-GAAP | FY2027 | $12.40 – $12.60 | – | New | Aug 11, 2026 |
| non-GAAP EPS growthnon-GAAP | FY2027 | +13% – +15% | – | New | Aug 11, 2026 |
| Non-GAAP adjusted free cash flownon-GAAP | FY2027 | $3.50B – $4.00B | – | New | Aug 11, 2026 |
| Capital Expenditures | FY2027 | $700.00M | – | New | Aug 11, 2026 |
| Diluted weighted average shares outstanding | FY2027 | 233 | – | New | Aug 11, 2026 |
| Interest and other | FY2027 | $240.00M – $290.00M | – | New | Aug 11, 2026 |
| Non-GAAP effective tax ratenon-GAAP | FY2027 | 19% – 20% | – | New | Aug 11, 2026 |
| Share repurchases | FY2027 | $1.00B | – | Raised | Aug 11, 2026 |
Guidance vs results
The last range Cardinal Health gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| FY2026 | non-GAAP diluted EPS attributable to Cardinal Health, Inc. | $10.70 – $10.80 | $11.26Σ4Q | Above range |
| FY2025 | non-GAAP diluted earnings per share attributable to Cardinal Health, Inc. | $8.05 – $8.15 | $8.24Σ4Q | Above range |
Guidance history
Every forecast Cardinal Health put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Aug 11, 2026 | Capital Expenditures | FY2027 | $700.00M | New |
| Aug 11, 2026 | non-GAAP EPS growth | FY2027 | +13% – +15% | New |
| Aug 11, 2026 | Non-GAAP earnings per share | FY2027 | $12.40 – $12.60 | New |
| Aug 11, 2026 | Non-GAAP adjusted free cash flow | FY2027 | $3.50B – $4.00B | New |
| Aug 11, 2026 | Segment profit | FY2027 | +8% – +11% | New |
| Aug 11, 2026 | Segment profit | FY2027 | $200.00M – $220.00M | New |
| Aug 11, 2026 | Segment profit | FY2027 | +15% – +18% | Raised |
| Aug 11, 2026 | Diluted weighted average shares outstanding | FY2027 | 233 | New |
| Aug 11, 2026 | Share repurchases | FY2027 | $1.00B | Raised |
| Aug 11, 2026 | Interest and other | FY2027 | $240.00M – $290.00M | New |
| Aug 11, 2026 | Non-GAAP effective tax rate | FY2027 | 19% – 20% | New |
| Aug 11, 2026 | Revenue | FY2027 | +3% – +5% | New |
| Aug 11, 2026 | Revenue | FY2027 | +2% – +4% | Lowered |
| Aug 11, 2026 | Revenue | FY2027 | +11% – +13% | Raised |
| Apr 30, 2026 | non-GAAP diluted EPS attributable to Cardinal Health, Inc. | FY2026 | $10.70 – $10.80 | Raised |
| Apr 30, 2026 | Adjusted free cash flow | FY2026 | $3.30B – $3.70B | Raised |
| Apr 30, 2026 | Other segment profit growth | FY2026 | +36% – +38% | Raised |
| Apr 30, 2026 | Pharmaceutical and Specialty Solutions segment profit growth | FY2026 | +22% – +23% | New |
| Apr 30, 2026 | Interest and Other expense | FY2026 | $340.00M | Raised |
| Apr 30, 2026 | Non-GAAP effective tax rate | FY2026 | 19% | Lowered |
| Apr 30, 2026 | Diluted weighted average shares outstanding | FY2026 | 237 | Lowered |
| Feb 5, 2026 | non-GAAP diluted EPS attributable to Cardinal Health, Inc. | FY2026 | $10.15 – $10.35 | Raised |
| Feb 5, 2026 | Global Medical Products and Distribution segment profit | FY2026 | $150.00M | New |
| Feb 5, 2026 | non-GAAP diluted EPS attributable to Cardinal Health, Inc. growth | FY2026 | +23% – +26% | New |
| Feb 5, 2026 | Non-GAAP effective tax rate | FY2026 | 21% – 23% | Lowered |
| Feb 5, 2026 | Diluted weighted average shares outstanding | FY2026 | 237 – 238 | Lowered |
| Feb 5, 2026 | Pharmaceutical and Specialty Solutions segment profit growth | FY2026 | +20% – +22% | Lowered |
| Feb 5, 2026 | Other segment profit growth | FY2026 | +33% – +35% | Raised |
| Oct 30, 2025 | Capital expenditures | FY2026 | $600.00M – $650.00M | Raised |
| Oct 30, 2025 | non-GAAP diluted EPS attributable to Cardinal Health, Inc. | FY2026 | $9.65 – $9.85 | Raised |
| Oct 30, 2025 | adjusted free cash flow | FY2026 | $3.00B – $3.50B | Raised |
| Oct 30, 2025 | Interest and other expense | FY2026 | $325.00M | Lowered |
| Oct 30, 2025 | Diluted weighted average shares outstanding | FY2026 | 238 | Lowered |
| Oct 30, 2025 | Other segment profit growth | FY2026 | +29% – +31% | Raised |
| Oct 30, 2025 | Pharmaceutical and Specialty Solutions segment profit growth | FY2026 | +16% – +19% | Lowered |
| Aug 12, 2025 | Capital Expenditures | FY2026 | $600.00M | New |
| Aug 12, 2025 | non-GAAP diluted EPS | FY2026 | $9.30 – $9.50 | New |
| Aug 12, 2025 | Non-GAAP adjusted free cash flow | FY2026 | $2.75B – $3.25B | New |
| Aug 12, 2025 | Other (NPHS, at-Home Solutions, OptiFreight Logistics) Revenue | FY2026 | +26% – +28% | Raised |
| Aug 12, 2025 | Global Medical Products and Distribution segment Revenue | FY2026 | +2% – +4% | Lowered |
| Aug 12, 2025 | Pharmaceutical and Specialty Solutions segment Segment profit | FY2026 | +11% – +13% | Reaffirmed |
| Aug 12, 2025 | Pharmaceutical and Specialty Solutions segment Revenue | FY2026 | +11% – +13% | New |
| Aug 12, 2025 | Non-GAAP effective tax rate | FY2026 | 22% – 24% | New |
| Aug 12, 2025 | Diluted weighted average shares outstanding | FY2026 | 238 – 240 | New |
| Aug 12, 2025 | Interest and other | FY2026 | $275.00M | Raised |
| Aug 12, 2025 | Global Medical Products and Distribution segment Segment profit | FY2026 | $140.00M | New |
| Aug 12, 2025 | Other (NPHS, at-Home Solutions, OptiFreight Logistics) Segment profit | FY2026 | +25% – +27% | Lowered |
| Aug 12, 2025 | Share repurchases | FY2026 | $750.00M | Raised |
| May 1, 2025 | non-GAAP diluted earnings per share attributable to Cardinal Health, Inc. | FY2025 | $8.05 – $8.15 | Raised |
| May 1, 2025 | Other segment profit | FY2025 | +16% – +18% | Raised |
| May 1, 2025 | Pharmaceutical and Specialty Solutions segment profit | FY2025 | +11.5% – +12.5% | New |
| May 1, 2025 | GMPD segment profit | FY2025 | $130.00M – $140.00M | New |
| May 1, 2025 | interest and other expense | FY2025 | $200.00M – $215.00M | Raised |
| May 1, 2025 | non-GAAP effective tax rate | FY2025 | 23% – 23.5% | New |
| May 1, 2025 | diluted weighted average shares outstanding | FY2025 | 242 | New |
| Jan 30, 2025 | non-GAAP diluted earnings per share attributable to Cardinal Health, Inc. | FY2025 | $7.85 – $8.00 | New |
| Jan 30, 2025 | interest and other expense | FY2025 | $200.00M – $230.00M | New |
| Jan 30, 2025 | GMPD segment profit | FY2025 | $130.00M – $150.00M | New |
| Jan 30, 2025 | Pharmaceutical and Specialty Solutions segment profit | FY2025 | +10% – +12% | New |
| Nov 1, 2024 | non-GAAP diluted earnings per share attributable to Cardinal Health, Inc. | FY2025 | $7.75 – $7.90 | Raised |
| Nov 1, 2024 | adjusted free cash flow | FY2025 | $1.00B – $1.50B | Raised |
| Nov 1, 2024 | Pharmaceutical and Specialty Solutions segment profit outlook | FY2025 | +4% – +6% | New |
| Nov 1, 2024 | Global Medical Products and Distribution segment profit outlook | FY2025 | $140.00M – $175.00M | New |
| Aug 14, 2024 | Capital Expenditures | FY2025 | $500.00M – $550.00M | New |
| Aug 14, 2024 | non-GAAP diluted EPS | FY2025 | $7.55 – $7.70 | Raised |
| Aug 14, 2024 | Non-GAAP adjusted free cash flow | FY2025 | $1.00B | New |
| May 2, 2024 | non-GAAP diluted earnings per share attributable to Cardinal Health, Inc. | FY2024 | $7.30 – $7.40 | Raised |
| May 2, 2024 | Non-GAAP Diluted EPS | FY2025 | $7.50 | New |
| May 2, 2024 | Pharmaceutical and Specialty Solutions Segment profit growth | FY2025 | +1% | New |
| May 2, 2024 | Pharmaceutical and Specialty Solutions segment profit outlook | FY2024 | +8.5% – +9.5% | Raised |
| May 2, 2024 | Global Medical Products and Distribution Segment profit | FY2025 | $175.00M | New |
| May 2, 2024 | Other Segment profit growth | FY2025 | +10% | Raised |
| May 2, 2024 | Non-GAAP Effective Tax Rate | FY2025 | 23% – 24% | New |
| May 2, 2024 | Interest and Other | FY2025 | $160.00M – $190.00M | New |
| May 2, 2024 | Diluted weighted average shares outstanding | FY2025 | 244 – 245 | New |
| May 2, 2024 | non-GAAP effective tax rate | FY2024 | 22% – 23% | Lowered |
| May 2, 2024 | Baseline share repurchases | FY2025 | $500.00M | Raised |
| Feb 1, 2024 | non-GAAP diluted earnings per share attributable to Cardinal Health, Inc. | FY2024 | $7.20 – $7.35 | Raised |
| Feb 1, 2024 | non-GAAP adjusted free cash | FY2024 | $2.50B | Raised |
| Nov 3, 2023 | non-GAAP diluted earnings per share attributable to Cardinal Health, Inc. | FY2024 | $6.75 – $7.00 | Raised |
| Nov 3, 2023 | Pharmaceutical segment profit | FY2024 | +7% – +9% | New |
| Nov 3, 2023 | interest and other | FY2024 | $100.00M – $120.00M | Lowered |
| Nov 3, 2023 | diluted weighted average shares outstanding | FY2024 | 249 | Lowered |
| Aug 15, 2023 | Capital Expenditures | FY2024 | $500.00M | New |
| Aug 15, 2023 | Non-GAAP earnings per share | FY2024 | $6.50 – $6.75 | New |
| Aug 15, 2023 | Non-GAAP adjusted free cash flow | FY2024 | $2.00B | New |
| Aug 15, 2023 | Pharmaceutical segment profit | FY2024 | +4% – +6% | New |
| Aug 15, 2023 | Medical segment: Segment profit | FY2024 | $400.00M | New |
| Aug 15, 2023 | Interest and other | FY2024 | $110.00M – $130.00M | New |
| Aug 15, 2023 | Diluted weighted average shares outstanding | FY2024 | 250 – 253 | New |
| Aug 15, 2023 | Non-GAAP effective tax rate | FY2024 | 23% – 25% | New |
| Aug 15, 2023 | Share repurchases | FY2024 | $500.00M | Raised |
| Aug 15, 2023 | Medical segment: Revenue | FY2024 | +3% | Lowered |
| Aug 15, 2023 | Pharmaceutical segment: Revenue | FY2024 | +10% – +12% | New |
| May 4, 2023 | capital expenditures | FY2023 | $450.00M | Lowered |
| May 4, 2023 | non-GAAP diluted earnings per share attributable to Cardinal Health, Inc. | FY2023 | $5.60 – $5.80 | Raised |
| May 4, 2023 | adjusted free cash flow | FY2023 | $2.00B – $2.30B | Raised |
| May 4, 2023 | Pharmaceutical segment profit outlook | FY2023 | +10.5% – +12% | New |
| May 4, 2023 | interest and other | FY2023 | $95.00M – $105.00M | Lowered |
| May 4, 2023 | Medical segment profit outlook | FY2023 | -50% | Lowered |
| May 4, 2023 | non-GAAP effective tax rate | FY2023 | 22% – 23% | Lowered |
| May 4, 2023 | diluted weighted average shares outstanding | FY2023 | 262 – 263 | Lowered |
| Feb 2, 2023 | non-GAAP diluted earnings per share attributable to Cardinal Health, Inc. | FY2023 | $5.20 – $5.50 | Raised |
| Feb 2, 2023 | Pharmaceutical segment profit outlook | FY2023 | +4% – +6.5% | New |
| Feb 2, 2023 | interest and other | FY2023 | $115.00M – $130.00M | New |
| Nov 4, 2022 | non-GAAP diluted earnings per share attributable to Cardinal Health, Inc. | FY2023 | $5.05 – $5.40 | Reaffirmed |
| Nov 4, 2022 | interest and other | FY2023 | $140.00M – $160.00M | Lowered |
| Nov 4, 2022 | non-GAAP effective tax rate | FY2023 | 23% – 24% | Lowered |
| Nov 4, 2022 | diluted weighted average shares outstanding | FY2023 | 262 – 264 | Lowered |
| Aug 11, 2022 | Capital Expenditures | FY2023 | $500.00M | New |
| Aug 11, 2022 | Non-GAAP earnings per share | FY2023 | $5.05 – $5.40 | New |
| Aug 11, 2022 | Adjusted free cash flow | FY2023 | $1.50B – $2.00B | New |
| Aug 11, 2022 | Diluted weighted average shares outstanding | FY2023 | 262 – 266 | New |
| Aug 11, 2022 | Interest and other | FY2023 | $140.00M – $170.00M | New |
| Aug 11, 2022 | Non-GAAP effective tax rate | FY2023 | 23% – 25% | New |
| Aug 11, 2022 | Share repurchases | FY2023 | $1.50B – $2.00B | Raised |
| May 5, 2022 | capital expenditures | FY2022 | $400.00M | New |
| May 5, 2022 | non-GAAP diluted earnings per share attributable to Cardinal Health, Inc. | FY2022 | $5.15 – $5.25 | Lowered |
| May 5, 2022 | diluted weighted average shares outstanding | FY2022 | 281 | Narrowed |
| May 5, 2022 | non-GAAP effective tax rate | FY2022 | 22% – 23% | Lowered |
| Feb 3, 2022 | non-GAAP diluted earnings per share attributable to Cardinal Health, Inc. | FY2022 | $5.15 – $5.50 | Lowered |
| Feb 3, 2022 | Interest and Other | FY2022 | $140.00M – $160.00M | New |
| Feb 3, 2022 | non-GAAP effective tax rate | FY2022 | 23% – 24.5% | Lowered |
| Nov 9, 2021 | non-GAAP diluted earnings per share attributable to Cardinal Health, Inc. | FY2022 | $5.60 – $5.90 | New |
| Nov 9, 2021 | non-GAAP effective tax rate | FY2022 | 23% – 25% | New |
| Nov 9, 2021 | diluted weighted average shares outstanding | FY2022 | 280 – 282 | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Cardinal Health filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Results
- Results
- Update
- Results
- Update
- Results
- Results
- Results
- Update
- Results
- Update
- Results
- Update
- Results